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Immunotherapeutic response in cancer patients, specifi-
cally those attributed to antibody-dependent cellular cyto-
toxicity (ADCC), may be variable dependent upon an
individual’s genotype. A recent Eastern Cooperative
Oncology Group (ECOG) Phase III clinical trial, E4402,
sought to optimize therapeutic administration of single
agent rituximab (RTX) in patients with low tumor burden
follicular lymphoma by investigating two RTX mainte-
nance strategies: Arm A (RTX given “as needed”) or Arm
B (continuous RTX regimen). We analyzed the DNA from
these patients to determine if KIR/KIR-ligand genotype
had an effect on patient response to RTX. Of several para-
meters assessed, the activating KIR2DS1 gene and its cog-
nate ligand, HLA-C2, were found to yield significant
associations with clinical outcome. Venstrom et al.
(NEJM-2012) found in an allogeneic setting that patients
receiving a hematopoietic stem cell transplant from
donors positive for KIR2DS1 (2DS1+) had a lower rate of
relapse than from 2DS1 negative (2DS1-) donors, and this
difference was further influenced by HLA-C. Specifically,
for 2DS1+ donors, the HLA-C1 positive (C1+) recipients
[homozygote (C1C1) or heterozygote (C1C2)] fared better
than recipients homozygous for HLA-C2 (C2C2).
In this study, we observed a similar finding, where 2DS1
+ patients had a trend towards better response (tumor
shrinkage) if they were C1+ rather than C2C2 (p=0.062),
as well as a longer time to RTX-failure (TTRF) (p<0.001).
Furthermore, we noted a trend towards a longer TTRF in
patients that were C1+ vs. those that were C2C2, regard-
less of KIR status (p=0.071). Interestingly, unlike Ven-
strom et al., we found that C2C2 patients had improved
tumor shrinkage (p=0.039) and improved TTRF (p=0.023)
if they were 2DS1- vs. 2DS1+. These results are consistent
with hyporesponsive NK cells in 2DS1+/C2C2 patients, as
shown by Pittari et al. [JI-2013], such that 2DS1+ NK cells
from C2C2 allogeneic donors were desensitized compared
to those from C1+ donors. This is analogous to studies
where the presence of an activating receptor and its cog-
nate ligand resulted in reduced responsiveness of NK cells.
Our data are concordant with previous findings in allo-
geneic settings. Our results suggest that C2 homozygosity
may contribute to NK cell hyporesponsiveness in a 2DS1-
dependent manner, even in an autologous immunotherapy
setting.
Authors’ details
1University of Wisconsin, Madison, WI, USA. 2Dana-Farber Cancer, Boston,
MA, USA. 3British Columbia Cancer Agency, Vancouver, BC, Canada.
4Montefiore Medical Center North Campus, Bronx, NY, USA. 5Genentech, Inc.,
South San Francisco, CA, USA.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P243
Cite this article as: Erbe et al.: Rituximab response in follicular
lymphoma: contributions from KIR 2DS1 and HLA-C. Journal for
ImmunoTherapy of Cancer 2013 1(Suppl 1):P243.
† Contributed equally
1University of Wisconsin, Madison, WI, USA
Full list of author information is available at the end of the article
Erbe et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P243
http://www.immunotherapyofcancer.org/content/1/S1/P243
© 2013 Erbe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
